The Food and Drug Administration (FDA) approved ferumoxytol, an intravenous iron therapy to treat iron deficiency in patients with chronic kidney disease (CKD) either on or off dialysis.  Ferumoxytol differs from current intravenous iron therapies in that it can be administered to patients more quickly.  Iron injections are given to patients with severe iron deficiency or those receiving erythropoiesis stimulating agents (ESAs), but only a doctor can determine if they are right for you.

This article originally appeared in the October 2009 issue of Kidney Beginnings: The Electronic Newsletter.